Cellectis S.A. Files 6-K Regarding BALLI-01 Study

Ticker: CLLS · Form: 6-K · Filed: Oct 17, 2025 · CIK: 1627281

Sentiment: neutral

Topics: regulatory-filing, clinical-study

TL;DR

Cellectis 6-K filed: BALLI-01 study update, incorporated into F-3/S-8 filings.

AI Summary

Cellectis S.A. filed a Form 6-K on October 16, 2025, reporting information related to its BALLI-01 Study. This filing incorporates information into existing registration statements on Form F-3 and Form S-8.

Why It Matters

This filing provides an update on the BALLI-01 Study, which is crucial for understanding the progress and potential future developments of Cellectis's therapeutic candidates.

Risk Assessment

Risk Level: low — This is a routine filing providing information and incorporating previous disclosures, not announcing new material events or financial results.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose is to report information under the caption "BALLI-01 Study" and to incorporate this information by reference into Cellectis S.A.'s existing registration statements on Form F-3 and Form S-8.

When was this Form 6-K filed with the SEC?

This Form 6-K was filed with the SEC on October 17, 2025, reporting information as of October 16, 2025.

What specific study is mentioned in this filing?

The filing specifically mentions the "BALLI-01 Study".

Which registration statements will incorporate the information from this 6-K?

The information will be incorporated into Cellectis S.A.'s registration statements on Form F-3 (No. 333-288491 and 333-284302) and Form S-8 (Nos. 333-204205, 333-214884, 333-222482, 333-227717, 333-258514).

What is Cellectis S.A.'s principal executive office address?

Cellectis S.A.'s principal executive office is located at 8, rue de la Croix Jarry, 75013 Paris, France.

Filing Stats: 1,068 words · 4 min read · ~4 pages · Grade level 12.9 · Accepted 2025-10-17 07:00:21

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CELLECTIS S.A. October 16, 2025 By: /s/ André Choulika André Choulika Chief Executive Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing